Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
122,541,881
-
Total 13F shares
-
71,600,840
-
Share change
-
+5,799,339
-
Total reported value
-
$787,595,702
-
Put/Call ratio
-
34%
-
Price per share
-
$11.00
-
Number of holders
-
141
-
Value change
-
+$44,255,428
-
Number of buys
-
87
-
Number of sells
-
51
Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT) as of Q1 2023
As of 31 Mar 2023,
Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT) was held by
141 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
71,600,840 shares.
The largest 10 holders included
FMR LLC, Frazier Life Sciences Management, L.P., BlackRock Inc., STATE STREET CORP, Rubric Capital Management LP, Polar Capital Holdings Plc, Bain Capital Life Sciences Investors, LLC, VANGUARD GROUP INC, MARSHALL WACE, LLP, and JENNISON ASSOCIATES LLC.
This page lists
141
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.